|

Pidnarulex Clinical Trials

4 actively recruiting trials across 4 locations

No change since May 2026

Also known as: CX-5461, CX5461, Pol I Inhibitor CX5461, RNA Pol I Inhibitor CX5461

Pipeline

Phase 1: 2Phase 1/2: 2

Top Sponsors

  • National Cancer Institute (NCI)4

Indications

  • Cancer4
  • Metastatic Malignant Solid Neoplasm2
  • Unresectable Colorectal Adenocarcinoma1
  • Double-Expressor Lymphoma1
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements1

Irvine, California1 trial

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1/2

Baltimore, Maryland1 trial

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Phase 1/2

Bethesda, Maryland1 trial

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

National Cancer Institute Developmental Therapeutics Clinic

Phase 1

St Louis, Missouri1 trial

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Washington University School of Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.